Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

诺华支付2,500万 美元和解关于在中国违反FCPA的指控

2016年3月25日, 科文顿电子期刊

2016年3月23日,诺华集团(“诺华”)同意支付2,500万美元就指控其违反美国《反海外腐败法》(“《反海外腐败法》”)的民事起诉与美国证券交易委员会(“证交会”)达成和解。诺华因于2009年至2013年间在中国向医疗专业人员(“医疗专业人员”)行贿以增加其药品销售而被起诉。其两家中国子公司的员工和经理企图利用有同谋关系的第三方代理掩盖不当付款,并将该等付款记录为用于旅行和招待、会议、教育活动和医疗研究的合法支出。该等账簿和记录后来被合并到诺华(在纽约证券交易所上市)的财务报告中。此行为导致违反 《反海外腐败法》下的账簿和记录以及内部会计控制规定。

Share this article: